Drug intelligence / Profile preview

sacituzumab tirumotecan + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sacituzumab tirumotecan + pembrolizumab is an investigational combination therapy under clinical development for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and gastroesophageal cancers. Sacituzumab tirumotecan (also known as MK-2870 or sac-TMT) is an antibody-drug conjugate targeting TROP2, consisting of a TROP2-targeting monoclonal antibody linked to a topoisomerase 1 inhibitor payload via a novel hydrolyzable linker. Pembrolizumab is a humanized monoclonal antibody that blocks the PD-1 receptor, enhancing anti-tumor immune responses. The combination aims to leverage targeted cytotoxicity against tumor cells with immune checkpoint inhibition to improve overall survival and disease control in patients with advanced malignancies[1][2][4][9].

Brand names: Keytruda (for pembrolizumab)
Other names: sacituzumab tirumotecan (sac-TMT) plus pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on sacituzumab tirumotecan + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacituzumab tirumotecan + pembrolizumab.

Explore the full profile